INFLUENZA VACCINES ADJUVANTS — CONTEMPORARY STATE


Cite item

Full Text

Abstract

Data on development and study of adjuvants for influenza vaccines against avian and seasonal influenza are presented. Requirements to perspective adjuvants, their main groups (mineral salts of aluminium, squalene derivatives, polyglycosides, and immunomodulators) as well as experimental adjuvants are reviewed. Analysis of results of several clinical trials of adjuvanted vaccines against avian influenza is presented. On the basis of published data analysis conclusion about good perspective of influenza vaccines with new adjuvants was made.

About the authors

Yu. M Vasiliev

Sechenov Moscow Medical Academy, Moscow, Russ

References

  1. Бурцева Е.И., Слепушкин А.Н., Власова Л.Н. и др. Опыт вакцинопрофилактики гриппа у лиц пожилого возраста. Реактогенность и иммуногенность инактивированных вакцин. Журн. микробиол. 2000, 5: 42-45.
  2. Гендон Ю.З. Вакцины и химиопрепараты для профилактики гриппа. Вопр. вирусол. 2007, 1: 4-10.
  3. Ельшина Г.А., Горбунов М.А., Шерварли В.И. и др. Оценка эффективности гриппозной тривалентной полимер-субъединичной вакцины «Гриппол». Журн. микробиол. 1998, 3: 40-43.
  4. Зверев В.В., Катлинский А.В., Костинов М.П. и др. Результаты сравнительного клинического исследования вакцин против вируса гриппа птиц. Там же. 2007, 3: 10-16.
  5. Aguilar J., Rodriguez E. Vaccine adjuvants revisited. Vaccine. 2007, 25: 3752-3762.
  6. Ansaldi F., Bacilieri S., Durando P. et al. Crossprotection by MF59 trade mark-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. Ibid. 2008, 26: 1525-1529.
  7. Atmar R., Keitel W., Patel S. et al. Safety and immunogenicity of nonadjuvanted and MF59adjuvanted influenza A/H9N2 vaccine preparations. Clin. Infect. Dis. 2006, 43: 1135-1142.
  8. Banzhoff A., Gasparini R., Laghi-Pasini F. et al. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS ONE. 2009, 4: e4384.
  9. Baras B., Stittelaar K., Simon J. et al. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. Ibid. 2008, 3: e1401.
  10. Bernstein D., Edwards K., Dekker C. et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J. Infect. Dis. 2008, 197: 667-675.
  11. Bungenera L., Geeraedtsa F., ter Veera W. et al. Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection. Vaccine. 2008, 26: 2350-2359.
  12. Chotpitayasunondh T., Thisyakorn U., Pancharoen C. et al. Safety, humoral and cell mediated immune responses to two formulations of an inactivated, split-virion influenza A/H5N1 vaccine in children. PLoS ONE. 2008, 3: e4028.
  13. Davenport F., Hennessy A., Askin F. Lack of adjuvant effect of AlPO4 on purified influenza hemagglutinins in man. J. Immunol. 1968, 100: 1139-1140.
  14. de Bruijn I., Meyer I., Gerez L. et al. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly. Vaccine. 2007, 26: 119-127.
  15. Ehrlich H., Müller M., Oh H. et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N. Engl. J. Med. 2008, 358: 2573-2584.
  16. Fazekas G., Martosne-Mendi R., Jankovics I. et al. Cross-reactive immunity in adult and elderly patients against clade 2 influenza A H5N1 virus strains induced by Fluval, a reverse genetic-derived adjuvanted H5N1 clade 1 prototype pandemic influenza vaccine. Clin. Vac. Immunol. 2008, CVI.00327-08v1.
  17. Federal Drug Administration. FDA approves first human avian influenza vaccine. http://www. fda.gov/bbs/topics/NEWS/2007/NEW01611. html.
  18. Francis T., Vaccination against influenza. Bull. WHO. 1953, 8: 725-741.
  19. Ghendon Y., Markushin S., Vasiliev Y. et al. Evaluation of chitosan properties as an adjuvant for parenterally administered inactivated influenza vaccine and inactivated avian influenza viruses. J. Med. Virol. 2009, 81: 494-506.
  20. Gioia C., Castilletti C., Tempestilli M. et al. Cross-subtype immunity against avian influenza in persons recently vaccinated for influenza. Emerg. Infect. Dis. 2008, 14: 121-128.
  21. Girard M., Palkonyay L., Kieny M. Report of the 4th meeting on the «Evaluation of pandemic influenza prototype vaccines in clinical trials». WHO 14-15 February 2008. Vaccine. 2008, 26: 4975-4977.
  22. Gupta R., Siber G. Adjuvants for human vaccines — current status, problems and future prospects. Ibid. 1995, 13: 1263-1276.
  23. Hehme N., Engelman H., Kuenzel W. et al. Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. Virus Res. 2004, 103: 163- 171.
  24. Jadhao S., Achenbach J., Swayne D. et al. Development of Eurasian H7N7/PR8 high growth reassortant virus for clinical evaluation as an inactivated pandemic influenza vaccine. Vaccine. 2008, 26: 1742-1750.
  25. Kamimura H., Koga N., Oguri K. et al. Studies on distribution, excretion and subacute toxicity of squalane in dogs. Fukuoka Igaku Zasshi. 1989, 80: 269-280.
  26. Keitel W., Campbell J., Treanor J. et al. Safety and Immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial. J. Infect. Dis. 2008, 198: 1309-1316.
  27. Kistner O., Howard M., Spruth M. et al. Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine. 2007, 25: 6028-6036.
  28. Lee L., Ha D., Simmons C. et al. Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J. Clin. Invest. 2008, 118: 3478-3490.
  29. Leroux-Roels I., Bernhard R., Gerard P. et al. Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS ONE. 2008, 3: e1665.
  30. Lin J., Zhang J, Dong X. et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet. 2006, 368: 991-997.
  31. Mkrtichyan M., Ghochikyan A., Movsesyan N. et al. Immunostimulant adjuvant patch enhances humoral and cellular immune responses to DNA immunization. DNA Cell Biol. 2008, 27: 19-24.
  32. Murakami S., Iwasa A., Iwatsuki-Horimoto K. et al. Cross-clade protective immunity of H5N1 influenza vaccines in a mouse model. Vaccine. 2008, 26: 6398-6404.
  33. Nolan T., Richmond P., Formica N. et al. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. Ibid. 2008, 26: 6383-6391.
  34. Onishi H., Machida Y. Biodegradation and distribution of water-soluble chitosan in mice. Biomaterials. 1999, 20: 175-182.
  35. Palache B. New vaccine approaches for seasonal and pandemic influenza. Vaccine. 2008, 26: 6232-6236.
  36. Palese P. How dangerous is H5 influenza? Another opinion. ESWI Inf. Bull. 2008, 23: 5-6.
  37. Pushko P., Tumpey T., Van Hoeven N. et al. Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza. Vaccine. 2007, 25: 4283-4290.
  38. Radosevic K., Rodriguez A., Mintardjo R. et al. Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: Impact of distinct additional adjuvants. Ibid. 2008, 26: 3640-3646.
  39. Read R., Naylor S., Potter C. et al. Effective nasal influenza vaccine delivery using chitosan. Ibid. 2005, 23: 4367-4374.
  40. Riedl K., Riedl R., von Gabain A. et al. The novel adjuvant IC31 strongly improves influenza vaccine-specific cellular and humoral immune responses in young adult and aged mice. Ibid. 2008, 26: 3461-3468.
  41. Ruat C., Caillet C., Bidaut A. et al. Vaccination of macaques with adjuvanted formalin-inactivated influenza A virus (H5N1) vaccines: protection against H5N1 challenge without disease enhancement. J. Virol. 2008, 82: 2565-2569.
  42. Rumke H., Bayas J., de Juanes J. et al. Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. Vaccine. 2008, 26: 2378-2388.
  43. Stephenson I., Bugarini R., Nicholson K. et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J. Infect. Dis. 2005, 191: 1210-1215.
  44. Stephenson I., Nicholson K., Hoschler K. et al. Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1. N. Engl. J. Med. 2008, 359: 1631-1633.
  45. Stephenson I., Zambon M., Rudin A. et al. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. J. Virol. 2006, 80: 4962-4970.
  46. Stowe J., Andrews N., Wise L. et al. Bell’s Palsy and parenteral inactivated influenza vaccine. Hum. Vacc. 2006, 2: 110-112.
  47. Wack A., Baudner B., Hilbert A. et al. Combina tion adjuvants for the induction of potent, longlasting antibody and T-cell responses to influenza vaccine in mice. Vaccine. 2007, 26: 552-561.
  48. Weibel R., McLean A., Woodhour A. et al. Ten year follow-up study for safety of adjuvant 65 influenza vaccine in man. Proc. Soc. Exp. Biol. Med. 1973, 143: 1053-1056.
  49. WHO. http://www.who.int/csr/disease/avian_influenza/en/index.html.
  50. Wood J., Williams M. History of inactivated influenza vaccine. In: Textbook of influenza. Blackwell Sci., 1998: p. 317-323.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Vasiliev Y.M.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС77-75442 от 01.04.2019 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies